Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Britt Duijndam

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Nucleic Acid Therapeutics|March 13, 2026
Reduced Genotoxicity Testing Is Possible for Noncoding Oligonucleotide-Based Therapeutics Containing Well-Characterized Modifications: A European Regulatory PerspectiveClara Stock, Britt Duijndam, Christine L E Siezen, et al.
Plos One|September 7, 2016
Human Cytochrome P450 2W1 Is Not Expressed in Adrenal Cortex and Is Only Rarely Expressed in Adrenocortical CarcinomasPaola Nolé, Britt Duijndam, Adam Stenman, et al.
RNA (New York, N.Y.)|January 20, 2023
Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerationsAnnemieke Aartsma-Rus, Willeke van Roon-Mom, Marlen Lauffer, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|March 26, 2021
Physiologically Relevant Estrogen Receptor Alpha Pathway Reporters for Single-Cell Imaging-Based Carcinogenic Hazard Assessment of Estrogenic CompoundsBritt Duijndam, Annabel Goudriaan, Tineke van den Hoorn, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|March 21, 2022
Evaluation of an imaging-based in vitro screening platform for estrogenic activity with OECD reference chemicalsBritt Duijndam, Massimo Tedeschi, Wanda van der Stel, et al.
Nucleic Acid Therapeutics|May 30, 2025
Developmental and Reproductive Toxicity Testing Strategies for Oligonucleotides: A Workshop ProceedingsBethany R Hannas, Sara M Bender, Eileen Blasi, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Nucleic Acid Therapeutics|March 13, 2026
Reduced Genotoxicity Testing Is Possible for Noncoding Oligonucleotide-Based Therapeutics Containing Well-Characterized Modifications: A European Regulatory PerspectiveClara Stock, Britt Duijndam, Christine L E Siezen, et al.
Plos One|September 7, 2016
Human Cytochrome P450 2W1 Is Not Expressed in Adrenal Cortex and Is Only Rarely Expressed in Adrenocortical CarcinomasPaola Nolé, Britt Duijndam, Adam Stenman, et al.
RNA (New York, N.Y.)|January 20, 2023
Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerationsAnnemieke Aartsma-Rus, Willeke van Roon-Mom, Marlen Lauffer, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|March 26, 2021
Physiologically Relevant Estrogen Receptor Alpha Pathway Reporters for Single-Cell Imaging-Based Carcinogenic Hazard Assessment of Estrogenic CompoundsBritt Duijndam, Annabel Goudriaan, Tineke van den Hoorn, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|March 21, 2022
Evaluation of an imaging-based in vitro screening platform for estrogenic activity with OECD reference chemicalsBritt Duijndam, Massimo Tedeschi, Wanda van der Stel, et al.
Nucleic Acid Therapeutics|May 30, 2025
Developmental and Reproductive Toxicity Testing Strategies for Oligonucleotides: A Workshop ProceedingsBethany R Hannas, Sara M Bender, Eileen Blasi, et al.
Pageof 1